RESMED INC (RMD): Results of Operations and Financial Condition
RESMED INC (RMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d158732dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 For investors For media +1 858-221-3304 +1 619-510-1281 investorrelations@resmed.com news@resmed.com Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026 • Q4 revenue increased by 9% to a record $1.5 bil
How this was made
The 30-second read
Why it matters
Traders can update valuation and positioning based on the disclosed earnings, margin trajectory, free cash flow, and the stated FY2027 capital return plan, alongside a pending MatrixCare divestiture and completed Noctrix acquisition.
Market read
A primary earnings and cash-flow disclosure with explicit FY2027 capital return guidance and a pending divestiture provides actionable inputs for near-term trading and medium-term expectations.
What to watch
The filing notes a $42M Astral field safety notification expense and a pending sale of MatrixCare; both can affect comparability and future segment earnings.
Background
This is Resmed’s SEC 8-K (Item 2.02) with its Q4 and full-year FY2026 results for the quarter ended June 30, 2026, plus FY2027 shareholder return guidance and business updates.
Ticker impact
Resmed reported Q4 FY2026 revenue up 9% to a record $1.5B, with GAAP EPS $2.64 and non-GAAP EPS $2.95.
Likely positive bias for the next session as traders price in stronger earnings, margin expansion, and higher shareholder returns.
The filing includes specific quarterly and full-year results, margin and EPS growth, free cash flow, and a concrete FY2027 capital return target of more than $1.85B.
Market effects
Supports the sleep-disordered breathing and medical device demand narrative via reported margin expansion and cash generation.
No explicit regional macro shock; growth is described across Americas and Rest of World on constant-currency terms.
Global product launches and partnerships (sleep health education) reinforce ongoing international commercialization momentum.
Counterpoint
Gross margin declined in Q4 GAAP terms (58.8% vs 60.8%) and free cash flow fell year over year, which could temper enthusiasm despite EPS growth.
Key entities
- companyResmed Inc.
NYSE-listed medical device company reporting Q4 and full-year FY2026 results and FY2027 capital return guidance.
- business_unitMatrixCare
Resmed business unit agreed for sale, expected to close in the first quarter of FY2027.
- acquisition_targetNoctrix Health
Medical device company acquired by Resmed, focused on FDA De Novo classified wearable therapeutics for RLS.
- partnerŌURA
Partnered with Resmed to expand sleep health education and pathways to care.
